Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3143490 | 0.95 | ALDH1A1 (0.66) | ALDH1A1PTPN11LCKCA1CA2 | |
| SCHEMBL69025 | 0.85 | PTPN11 (0.68) | ALDH1A1PTPN11LCKCA1CA2 | |
| SCHEMBL29365729 | 0.85 | PTPN11 (0.68) | ALDH1A1PTPN11LCKCA1CA2 | |
| SCHEMBL4590567 | 0.85 | PTPN11 (0.53) | ALDH1A1PTPN11LCKCA1CA2 | |
| SCHEMBL13395884 | 0.84 | ALDH1A1 (0.51) | ALDH1A1PTPN11LCKCA1CA2 | |
| SCHEMBL8732524 | 0.83 | PTPN11 (0.66) | ALDH1A1PTPN11LCKCA1CA2 | |
| SCHEMBL12942158 | 0.83 | PARP10 (0.45) | ALDH1A1PTPN11LCKPLAULMNA | |
| SCHEMBL9921935 | 0.82 | CA12 (0.53) | ALDH1A1PTPN11CA1CA2CA12 | |
| SCHEMBL79533 | 0.81 | ALDH1A1 (1.00) | ALDH1A1CA1CA2CA12CA7 | |
| SCHEMBL9979782 | 0.81 | PTPN11 (0.64) | ALDH1A1PTPN11LCKCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-10101780-A | — | — | None | — | — | JP | disclosed |
| CN-113842665-A | Leaching tower, system and method for purifying ester compounds | 中国石油化工股份有限公司 | 2021-12-28 | — | — | CN | disclosed |
| WO-2021087061-A2 | CRYSTALLIZABLE RESINS | ALIGN TECHNOLOGY, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| EP-2688568-B1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-06-19 | — | — | EP | disclosed |
| US-10064854-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-09-04 | — | — | US | disclosed |
| US-20180000805-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| US-9795597-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-10-24 | — | — | US | disclosed |
| US-20160220547-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-9346840-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-05-24 | — | — | US | disclosed |
| US-20140371176-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-12-18 | — | — | US | disclosed |
| EP-1019357-A1 | PROCESS FOR THE PURIFICATION OF NAPHTHALENEDICARBOXYLIC ACID | EASTMAN CHEMICAL COMPANY (US) | 2000-07-19 | — | — | EP | disclosed |
| US-6013831-A | ESTERIFYING 2,6-NAPHTHALENEDICARBOXYLIC ACID OBTAINED BY LIQUID PHASE OXIDATION OF 2,6-DIALKYLNAPHTHALENE WITH MOLECULAR OXYGEN IN THE PRESENCE OF A RECOVERABLE OXIDATION CATALYST; CONTINUOUS SUPPLY OF METHANOL | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2000-01-11 | — | — | US | disclosed |
| WO-1999018062-A1 | PROCESS FOR THE PURIFICATION OF NAPHTHALENEDICARBOXYLIC ACID | EASTMAN CHEMICAL COMPANY (US) | 1999-04-15 | — | — | WO | disclosed |
| EP-0877012-A2 | Process for the production of high-purity dimethyl 2,6-naphthalenedicarboxylate and naphthalenedicarboxylic acid | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1998-11-11 | — | — | EP | disclosed |
| US-5776365-A | COMPOUNDS WITH OPTICAL ACTIVITY AND SWITCHES FOR CONTRAST | MITSUI CHEMICALS, INC. (JP) | 1998-07-07 | — | — | US | disclosed |
| JP-H10101780-A | PRODUCTION OF POLYETHYLENE 2,6-NAPHTHALATE, POLYETHYLENE 2,6-NAPHTHALATE, AND SUPPORT FOR SILVER HALIDE PHOTOGRAPHIC FILM | FUJI PHOTO FILM CO LTD | 1998-04-21 | — | — | JP | disclosed |
| US-5725798-A | CARBOXYLIC ESTERS FOR ELECTRICAL APPARATUS, SWITCHES AND CONTRAST | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1998-03-10 | — | — | US | disclosed |
| US-4734406-A | 3-pyridylmethylnaphthyl derivatives and composition containing them useful to inhibit thromboxane synthetase | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-03-29 | — | — | US | disclosed |
| US-4518609-A | ANTITUMOR, SKIN DISORDERS | SRI INTERNATIONAL (US) | 1985-05-21 | — | — | US | disclosed |
| US-4456618-A | ANTITUMOR AGENTS, TREATMENT OF SKIN DISORDERS | SRI INTERNATIONAL (US) | 1984-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10064854-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM3B | ALDH1A1 554/4885PTPN11 3378/4885LCK 425/4885 |
| US-20160220547-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | ALDH1A1 554/4885PTPN11 3378/4885LCK 425/4885 |
| US-20180000805-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | ALDH1A1 554/4885PTPN11 3378/4885LCK 425/4885 |
| US-20140371176-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | ALDH1A1 554/4885PTPN11 3378/4885LCK 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.